| MannKind Corporation Q1 2010 Earnings Call Transcript MannKind Corporation (MNKD)Q1 2010 Earnings Call TranscriptApril 30, 2010 9:00 am ETComplete Story » seekingalpha.com |
When Food, Pills Clash The health-improving qualities of foods such as olive oil, nuts and fruit can interact with medications that people are already taking, causing possible problems. online.wsj.com |
BioClinica to Release Second Quarter 2010 Financial Results on August 4, 2010 (Business Wire) NEWTOWN, Pa.----BioClinica, Inc. will release its financial results for the second quarter ended June 30, 2010 on Wednesday, August 4, 2010. us.rd.yahoo.com |
ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer [PR Newswire] - eResearchTechnology, Inc. , , a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced that Michael McKelvey will be retiring from his positions as President and Chief Executive Officer and a director of ERT. Â The Company's Board of Directors has begun a search for a successor. Â Dr. us.rd.yahoo.com |
Seattle Genetics and Immunogen: Fabless Biotechs? Jason Chew submits: The results are in and it appears Seattle Genetics’ Antibody Drug Conjugate (ADC) technology does indeed work after all- not that that should be a surprise to anyone following the company. Results released early Monday morning showed 75% of relapsed or refractory Hodgkin's Lymphoma (HL) patients taking the drug Brentuximab Vendotin, or as I prefer to call it, SGN-35, in this pivotal Phase II trial achieved an objective response with a median duration of greater than six months... Applause.This is the second major trial to validate ADCs. Last year, Genentech (DNA), in collaboration with Immunogen, showed impressive responses with their ADC, Trastuzumab-DM1, in a Phase II trial for refractory HER2 positive breast cancer patients.Complete Story » seekingalpha.com |